title: Altered expression of long non-coding RNAs during genotoxic stress-induced cell death in human glioma cells.
abstract: Long non-coding RNAs (lncRNAs), a recently discovered class of non-coding genes, are transcribed throughout the genome. Emerging evidence suggests that lncRNAs may be involved in modulating various aspects of tumor biology, including regulating gene activity in response to external stimuli or DNA damage. No data are available regarding the expression of lncRNAs during genotoxic stress-induced apoptosis and/or necrosis in human glioma cells. In this study, we detected a change in the expression of specific candidate lncRNAs (neat1, GAS5, TUG1, BC200, Malat1, MEG3, MIR155HG, PAR5, and ST7OT1) during DNA damage-induced apoptosis in human glioma cell lines (U251 and U87) using doxorubicin (DOX) and resveratrol (RES). We also detected the expression pattern of these lncRNAs in human glioma cell lines under necrosis induced using an increased dose of DOX. Our results reveal that the lncRNA expression patterns are distinct between genotoxic stress-induced apoptosis and necrosis in human glioma cells. The sets of lncRNA expressed during genotoxic stress-induced apoptosis were DNA-damaging agent-specific. Generally, MEG3 and ST7OT1 are up-regulated in both cell lines under apoptosis induced using both agents. The induction of GAS5 is only clearly detected during DOX-induced apoptosis, whereas the up-regulation of neat1 and MIR155HG is only found during RES-induced apoptosis in both cell lines. However, TUG1, BC200 and MIR155HG are down regulated when necrosis is induced using a high dose of DOX in both cell lines. In conclusion, our findings suggest that the distinct regulation of lncRNAs may possibly involve in the process of cellular defense against genotoxic agents.
authors: Institute of Neuroscience, Chongqing Medical University, Chongqing, 400016, People's Republic of China.
authors: Qian
authors: Q
authors: Liu
authors: Shanquan
authors: S
authors: Sun
authors: Wei
authors: W
authors: Yu
authors: Jin
authors: J
authors: Jiang
authors: Fei
authors: F
authors: Zhuo
authors: Guoping
authors: G
authors: Qiu
authors: Shiye
authors: S
authors: Xu
authors: Xuli
authors: X
authors: Jiang
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D045744:Cell Line, Tumor; D004249:DNA Damage / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D004317:Doxorubicin / Q000494:pharmacology; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009336:Necrosis / Q000139:chemically induced* / Q000235:genetics / Q000378:metabolism; D062085:RNA, Long Noncoding / Q000378:metabolism*; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology
chemical_list: D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; C561567:GAS5 long non-coding RNA, human; C557041:MALAT1 long non-coding RNA, human; C498907:MEG3 non-coding RNA, human; C577276:NEAT1 long non-coding RNA, human; D062085:RNA, Long Noncoding; D013267:Stilbenes; C000598536:TUG1 long noncoding RNA, human; D004317:Doxorubicin; D000077185:Resveratrol
references: Invest New Drugs. 2005 Mar;23(2):111-9
references: 15744586
references: PLoS One. 2012;7(4):e34949
references: 22532836
references: Clin Exp Med. 2013 May;13(2):119-26
references: 22487937
references: J Cell Biochem. 2012 Jun;113(6):1868-74
references: 22234798
references: Sci Signal. 2010 Feb 02;3(107):ra8
references: 20124551
references: Oncogene. 2009 Jan 15;28(2):195-208
references: 18836484
references: Genome Res. 2009 Mar;19(3):347-59
references: 19106332
references: Nature. 2009 Mar 12;458(7235):223-7
references: 19182780
references: Bioessays. 2010 Jul;32(7):599-608
references: 20544733
references: Nucleic Acids Res. 2013 May;41(9):4976-87
references: 23558749
references: Mol Cell Biol. 2008 May;28(9):3008-19
references: 18316401
references: Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11667-72
references: 19571010
references: Curr Drug Targets. 2006 Apr;7(4):423-42
references: 16611030
references: Biochim Biophys Acta. 2013 Oct;1832(10):1613-23
references: 23676682
references: J Pathol. 2005 Oct;207(2):243-9
references: 16041695
references: Genomics. 2002 Sep;80(3):283-94
references: 12213198
references: J Pathol. 1997 Nov;183(3):345-51
references: 9422992
references: Oncol Rep. 2006 Sep;16(3):617-24
references: 16865264
references: Mol Cancer Ther. 2005 Apr;4(4):554-61
references: 15827328
references: BMC Neurosci. 2010 Feb 05;11:14
references: 20137068
references: Nat Genet. 2011 Jun 05;43(7):621-9
references: 21642992
references: Gene. 2013 Dec 10;532(1):1-12
references: 23246696
references: Biochim Biophys Acta. 2006 Nov;1760(11):1657-66
references: 17052855
references: Cell Res. 2013 Mar;23(3):340-50
references: 23208419
references: Nat Rev Cancer. 2002 Mar;2(3):188-200
references: 11990855
references: J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6
references: 10480340
references: Neuro Oncol. 2013 Nov;15 Suppl 2:ii1-56
references: 24137015
references: Clin Cancer Res. 2002 Mar;8(3):893-903
references: 11895924
references: Cell. 2009 Feb 20;136(4):629-41
references: 19239885
references: Trends Cell Biol. 2011 Jun;21(6):354-61
references: 21550244
references: Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32
references: 15738415
references: Nat Rev Genet. 2009 Mar;10(3):155-9
references: 19188922
references: Cell Mol Life Sci. 2009 Dec;66(24):3967-78
references: 19784808
references: Hum Mol Genet. 2010 Oct 15;19(R2):R152-61
references: 20729297